On 7 September 2026, LDROBOT (01236.HK) voluntarily announced that its shares had been included in the eligible securities lists of Stock Connect under both the Shanghai-Hong Kong and Shenzhen-Hong Kong schemes, effective from the same day, following the notices issued by the two exchanges. The company believes the inclusion will enhance its capital market recognition, broaden its shareholder base and improve share liquidity.
On 7 September 2026, OCT (ASIA) (03366.HK) announced that it plans to dispose of the entire equity interest in OCT (Changshu) Investment, an indirect wholly-owned subsidiary engaged in industrial park operation and leasing, through an open listing process on the Beijing Equity Exchange, with the potential disposal expected to constitute a major transaction under Chapter 14 of the Listing Rules if materialized. The target recorded revenue of RMB 3.24 million and net profit of RMB 0.37 million in H1 2026, with total assets of RMB 80.81 million and total liabilities of RMB 6.96 million as of 30 June 2026. The disposal is at the preliminary information disclosure stage, subject to conditions precedent including shareholders' approval, and is independent of the potential disposal of OCT (Changshu) Industrial Development announced on the same date.
On 7 September 2026, CM BANK (03968.HK) announced that assistant general manager Mr. Wang Xinghai had resigned due to work reasons, effective from the same day. He confirmed no disagreement with the board and no unfulfilled public commitments, will no longer hold any position in the company or its controlled subsidiaries after his resignation, and has completed the handover of his duties.
On 7 September 2026, CSPC PHARMA (01093.HK) voluntarily announced the official initiation of the Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults at the first center in China. SYH2085 is a Class 1 chemical small-molecule inhibitor targeting the PA subunit of the influenza virus RNA polymerase; the group obtained an NMPA Clinical Trial Approval Notice in December 2025, and Phase I data have preliminarily validated its safety and pharmacokinetic/pharmacodynamic profiles, while the multicenter, randomized, double-blind, placebo-controlled Phase II study is now recruiting and screening participants.
On 7 September 2026, CENTRALCHINA MT (09982.HK) announced that executive director Ms. Liu Lin and company secretary and authorized representative Mr. Xie Ziqian had resigned, both effective from the same day. Following Mr. Xie's resignation, the company is temporarily non-compliant with Rules 3.05 and 3.28 of the Listing Rules; the board will identify replacements as soon as possible, with executive director Mr. Wang Kai and external company secretarial service providers and/or legal advisers assisting with compliance matters in the interim.
On 7 September 2026, MICROTECH MED-B (02235.HK) voluntarily announced that its next-generation patch-style continuous glucose monitoring system AiDEX G9 had obtained marketing approval from the NMPA, featuring an innovative change in technical architecture and comprehensive upgrades in size, lightweight design and wearing comfort over the first-generation product. Citing the IDF Diabetes Atlas 2025, the announcement noted that approximately 148 million Chinese adults aged 20-79 were living with diabetes in 2024, ranking first globally, with 274 million adults with prediabetes.
On 7 September 2026, SBP GROUP (01177.HK) voluntarily announced that TQC3721 dry powder inhaler, a PDE3/4 inhibitor developed by its subsidiary Chia Tai Tianqing, had two Phase I datasets presented at ERS 2026: a dose-ranging study in 72 COPD patients showed dose-dependent improvements in peak FEV1 at Day 9 (from 300.0 mL in the 125 μg group to 497.0 mL in the 1000 μg group), and a proof-of-concept study of the combination with glycopyrronium bromide (40 patients) showed clinically meaningful improvements versus the IND/GLY control, with FEV1 trough improving 203 mL and peak 110 mL from baseline. The nebulized suspension formulation of TQC3721 is in Phase III in China and has received CDE breakthrough therapy designation.
On 7 September 2026, TIMES CHINA (01233.HK) announced its unaudited operational data for the eight months ended 31 August 2026, recording contracted sales (including contracted sales of joint venture projects) of approximately RMB 205 million with contracted GFA of approximately 16,900 sq.m. in August, and cumulative contracted sales of approximately RMB 2.237 billion with cumulative contracted GFA of approximately 219,700 sq.m. for the eight-month period.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that it had received NMPA Clinical Trial Approval Notices for HRS-6209 capsules and HRS-4508 tablets, approving an open-label, multicenter Phase Ib/II study of HRS-6209 in combination with other anti-tumor therapies in advanced unresectable or metastatic breast cancer and of HRS-9813 in advanced solid tumors. HRS-6209 is a novel selective CDK4 inhibitor that has advanced into Phase II, and HRS-4508 tablets are a novel selective tyrosine kinase inhibitor; cumulative R&D investment in the two projects amounts to approximately RMB 160.9 million and RMB 96.7 million respectively.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Shandong Shengdi Pharmaceutical had received an NMPA Clinical Trial Approval Notice for HRS-1597 tablets, approving clinical trials for the weight management indication. The drug is a Class 1 innovative drug independently developed by the company with no similar drug yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 16.9 million.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that its subsidiary Guangdong Hengrui Pharmaceutical had received an NMPA Clinical Trial Approval Notice for SHR-1179 injection, approving clinical trials for the weight management indication. The drug is a therapeutic Class 1 biological product independently developed by the company, with no drug targeting the same pathway yet approved in China or overseas, and cumulative R&D investment in the project of approximately RMB 24.2 million.
On 7 September 2026, CHINA OVERSEAS (00688.HK) announced that China Asset Management and CITIC Securities had submitted application materials for the registration and listing of a public commercial REIT with the CSRC and the SZSE. The company proposes to spin off the Foshan Qiandeng Lake Unicenter shopping mall project into a public REIT for independent listing on the SZSE, with expected gross proceeds of approximately RMB 1.534 billion and a group subscription for approximately 20% of the issued fund units, after which the project company will be 100% held by the REIT and deconsolidated. As all applicable percentage ratios are below 5%, the proposed spin-off is not subject to the Chapter 14 reporting, announcement or shareholders' approval requirements, and the company has applied for a waiver from the assured entitlement requirement under paragraph 3(f) of Practice Note 15.
On 7 September 2026, CIFI HOLD GP (00884.HK) announced its unaudited operational data for August 2026, recording contracted sales (including contracted sales of joint ventures and associates) of approximately RMB 660 million with contracted sales area of approximately 62,400 sq.m. and an average contracted selling price of approximately RMB 11,700 per sq.m. in the month, and cumulative contracted sales of approximately RMB 6.30 billion with contracted sales area of approximately 649,800 sq.m. and shareholders' attributable contracted sales of approximately RMB 3.33 billion for January to August 2026.
On 7 September 2026, AGILE GROUP (03383.HK) announced its unaudited operational data for August 2026, recording aggregate pre-sales of approximately RMB 380 million with a corresponding floor area of approximately 46,000 sq.m. at an average price of RMB 8,234 per sq.m. in the month, and cumulative pre-sales of approximately RMB 4.67 billion with a floor area of approximately 520,000 sq.m. at an average price of RMB 8,977 per sq.m. for the eight months ended 31 August 2026.
On 7 September 2026, CIL GROUP (01719.HK) announced that its wholly-owned subsidiary had entered into a limited partnership agreement with Changjiang Venture Capital, Hubei Ganghang and Wuhan Ganghang to establish a port and shipping development fund with total capital commitments of RMB 300 million (approximately HKD 351 million), to which the subsidiary will contribute RMB 8 million, representing about 2.66%. As the counterparties are associates of controlling shareholder Hubei Port Group, the transaction constitutes a connected transaction; with the highest applicable percentage ratio exceeding 0.1% but below 5%, it is subject to reporting and announcement requirements but exempt from circular and independent shareholders' approval.
On 7 September 2026, SHOUGANG LANZA (02553.HK) voluntarily announced that its H shares had been included in the eligible securities list of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect (collectively, Stock Connect), effective from the same day, enabling eligible mainland investors to buy and sell its H shares directly through the scheme, which is expected to broaden the company's investor base and may increase the trading liquidity of its H shares.
